AVEO Pharmaceuticals Inc

AVEO Pharmaceuticals — Investor Presentation (April 2017)

32 slides from AVEO Pharmaceuticals's investor presentation, Apr 5, 2017

  1. Slide 1: AVEO Overview April 2017

    AVEO Overview April 2017 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements. The words “anticipate,” “believe,” “estimate,”

  3. Slide 3: Multiple Opportunities for Potential Value Creation

    TIVO-1 (1st Line RCC) * Ocular SCCHN / AML (Investigator) Esophageal Cancer Cachexia TIVO-3 (U.S. Phase 3 Registration Study in RCC) TiNivo (+Opdivo® RCC) PAH Multiple Opportunities for Potential Value Creation *Filed in EU by EUSA FEB 2016 EUSA received 180 day outstanding issues JAN 2017 Seeking P

  4. Slide 4: Tivozanib Potential Milestone Timeline in RCC

    Tivozanib Potential Milestone Timeline in RCC MAA Review TIVO-3 : Tivo v. Sorafenib US Regulatory Decision EU Regulatory Decision NDA Review 2016 2017 2018 2019 2020 Ph 2 Expansion Potential NDA Filing 2H 2018 PFS Data/OS Trend Estimated 1Q 2018 Ph 1 Data Estimated 1H 2017 Ph 1 Tivo + Opdivo® Potent

  5. Slide 5: Large and Growing RCC Opportunity

    Large and Growing RCC Opportunity ~$1.7 Billion* ~$1.4 Billion* * Total RCC market includes all stages of disease and treatment options. Source: GlobalData Forecast 2023 Market opportunity expected to grow to >$3 billion in Europe and North America* Market needs: Improved tolerability in first line

  6. Slide 6: Tivozanib AVEO's North American Registration Strategy

    Tivozanib AVEO’s North American Registration Strategy

  7. Slide 7: Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor

    Tivozanib: VEGFR 1, 2 and 3 Tyrosine Kinase Inhibitor Potent, selective inhibitor of VEGFRs 1, 2 and 3 with a long half-life that is designed to optimize blockade while minimizing off-target toxicities1,2 1. Nakamura K et al. Cancer Res 2006;66:9134–9142. 2. Eskens FA et al. Clin Cancer Res 2011;17:

  8. Slide 8: TIVO-1: Unsurpassed PFS in 1st Line RCC

    TIVO-1: Unsurpassed PFS in 1st Line RCC in Phase 3 517 patient, global, randomized Phase 3 in 1st line RCC First H2H RCC pivotal to meet primary PFS endpoint of superiority vs VEGF TKI OS confounded by crossover; NDA not approved; FDA requested additional study Demonstrated favorable tolerability pr

  9. Slide 9: Top Three Toxicities Relevant to Patients with Advanced RCC

    Top Three Toxicities Relevant to Patients with Advanced RCC* *Wong M, et al. J Med Econ. 2012;28:1-10. Additional months of PFS benefit patients require to accept adverse events >50% of pts on Nexavar <15% for Tivozanib >60% of pts on Sutent <20% for Tivozanib >50% of pts on Pazopanib, Axitinib and

  10. Slide 10: Tivozanib is Well Tolerated, Potential Preferred TKI for PD-1 Combination

    Tivozanib is Well Tolerated, and Has the Potential to Become the Preferred TKI for PD-1 Combination Therapy Single Agent Toxicity All grade (Gr 3/4) Sutent1 (n=548) Votrient1 (n=554) Inlyta5 (n=189) Nexavar3 (n=257) Lenvima4 (n=52) Cometriq2 (n=331) Tivozanib3 (n=259) Hypertension 30% (15%) 40% (4%)

  11. Slide 11: Favorable Tolerability vs. Approved TKIs in RCC

    Favorable Tolerability vs. Approved TKIs in RCC Incidence (%) Incidence (%) Tivozanib1 Sorafenib Pazopanib3 Axitinib2 TIVO-11 AXIS2 Sunitinib4 Dose Reductions Dose Interruptions Tivozanib1 Sorafenib Pazopanib3 Axitinib2 TIVO-11 AXIS2 Sunitinib4 Cabozantinib5 Lenvatinib+Everolimus6 1. Motzer et.al. J

  12. Slide 12: Tivozanib Uniquely Positioned in 1st Line RCC

    ? 1 Motzer, et. al. ESMO 2012 (COMPARZ): 1st Line study, sutent vs. votrient. 2 Hutson, et. al. Lancet Oncol 2013; 14: 1245; 1st line Phase 3 study vs sorafenib. 3 Motzer, et. al. JCO Oct 2013; 1st Line TIVO-1 Phase 3 study, tivozanib vs. sorafenib. 4 Choueri, et. al. ESMO 2016. Poor and Intermediat

  13. Slide 13: TIVO-3: Phase 3 Study Design in Recurrent/Metastatic RCC

    TIVO-3: Phase 3 Study Design in Recurrent/Metastatic RCC to Confirm TIVO-1 N = ~322 F Recurrent/metastatic RCC Failed at least two prior regimens including VEGFR-TKI (not sorafenib) ECOG PS 0 or 1 RANDOMIZE 1:1 tivozanib sorafenib 1O: PFS 2O: OS, ORR, DoR, Safety and Tolerability for ITT Designed to

  14. Slide 14: Tivozanib Efficacy in VEGF TKI Refractory Setting

    Tivozanib Efficacy in VEGF TKI Refractory Setting * n= 389; investigator assessed PFS; independent PFS = 4.8 mo vs. 3.4 mo, HR = 0.741 (p=0.011) **investigator assessed PFS ^cabozantinib USPI 1. Motzer et al Lancet Oncol 2013; 14: 552–62 2. Motzer et al Lancet Oncol 2014 3. Hutson et al ASCO 2015 4.

  15. Slide 15: Tivozanib European Registration Strategy

    Tivozanib European Registration Strategy

  16. Slide 16: EUSA Pharma Oncology Licensing Agreement

    EUSA Pharma Oncology Licensing Agreement Specialty pharmaceutical company with commercial operations in the US and Europe, distribution network in 40 countries Spinout of Jazz Pharmaceuticals (March 2015) EU filing February 2016, received day 180 List of Outstanding Issues January 2017 LOI signifies

  17. Slide 17: Support for Tivozanib MAA Filing for RCC

    Support for Tivozanib MAA Filing for RCC TIVO-1: Impact of Next-Line Therapy on OS * EU includes Bulgaria, Czech Republic, France, UK, Hungary, Italy, Poland, Romania (countries with patients enrolled in Study 301) ** EU5 includes UK, Italy, and France (EU5 countries with patients enrolled in Study

  18. Slide 18: Tivozanib PD-1 Combination Setting

    Tivozanib PD-1 Combination Setting

  19. Slide 19: Rationale for Combining VEGF + PD-(L)1 Inhibitors

    Rationale for Combining VEGF + PD-(L)1 Inhibitors Gunturi, McDermott Current Treatment Options in Oncology 2014 Plimack International Kidney Cancer Symposium 2014

  20. Slide 20: Tivozanib has Immunomodulatory Properties

    Tivozanib has Immunomodulatory Properties: Regulatory T Cell Reduction May Enhance PD-1 Activity Pawlowski N et al. AACR 2013. Poster 3971. Regulatory T cells suppress or downregulate induction and proliferation of effector T cells (e.g. CD4 and CD8) P=0.034

  21. Slide 21: Early Data for the Combination of PD-1 + VEGF TKIs

    Early Data for the Combination of PD-1 +VEGF TKIs: Demonstrated Promising Responses with Challenging Toxicity 1 Atkins et. al., ESMO 2016 2 Larkin et. al., ESMO 2016 Phase Ib dose-finding studies of axitinib plus pembrolizumab or avelumab in treatment-naïve patients with advanced renal cell carcinom

  22. Slide 22: Sunitinib & Pazopanib Have Overlapping Toxicities with PD-1s

    Sunitinib & Pazopanib, the most widely used VEGF TKIs, have potentially prohibitive overlapping toxicities with PD-1s Courtesy of Dr. S. Pal, ASCO GU 2015

  23. Slide 23: Significant TKI Dose Reductions Recommended to Combine with PD1s

    Significant reductions of TKI dose to manage AEs have been recommended to safely combine some TKIs with PD1s in RCC CaboNivo1: Cabo recommended dose reduction from 60 to 40mg Lenvatinib + Pembro2: Lenv recommended dose reduction 24 to 20mg Reduced Dose May Adversely Impact Efficacy 1 Apolo et. al.,

  24. Slide 24: Phase 1/2 TiNivo Study

    Phase 1 TiNivo Study Tivozanib (1.0 mg/day) QD/21 days + nivolumab 240 mg Q 2 weeks N = 6 - 12 ECOG PS ≤ 1 and life expectancy ≥ 3 months Tivozanib (1.5 mg/day) QD/21 days + nivolumab 240 mg Q 2 weeks Further evaluate the antineoplastic activity and safety Phase 1* Phase 2 Maximum tolerated dose N =

  25. Slide 25: High Potential Value Pipeline Programs

    High Potential Value Pipeline Programs

  26. Slide 26: Advancing Robust Pipeline Through Partnership

    Advancing Robust Pipeline Through Partnership Milestone and royalty payments subject to the successful development and/or commercialization of the product *Subject to milestone payment & royalty payment obligations to SVH AV-380 (GDF-15 inhibitor MAb) Indication: cachexia Incidence: 5M+ in US alone

  27. Slide 27: AV-353: 1st-in-class Opportunity in Pulmonary Arterial Hypertension

    AV-353: 1st-in-class opportunity to address major unmet need in pulmonary arterial hypertension (PAH) as potential to be first drug with disease modifying properties Binding specificity to Notch 3 reduces risks of pan-Notch toxicities that have hampered competitors Large Market Opportunity 2014 sale

  28. Slide 28: Financials and Portfolio Summary

    Financials and Portfolio Summary

  29. Slide 29: Financial Highlights

    Financial Highlights Cash on hand would fund planned operations into 2Q 2018*; beyond TIVO-3 readout which is expected 1Q 2018. $23.3M in cash and investments as of 4Q 2016 $15.5M in net proceeds from March 2017 public offering $0.5M milestone payment received from CANbridge March 2017 Potential acc

  30. Slide 30: Potential Corporate Milestones

    Potential Corporate Milestones 2017 2018 Regulatory decision in EU (1H17) TIVO-3 PFS data/OS trend (1Q18) Development milestones for AV-380 Manufacturing transfer (2107) and re-initiation of AV-203 clinical dev. (2018) Phase 1 data (1H17) TIVO-3 enrollment completion (June 2017) Pre-planned futility

  31. Slide 31: AVEO Oncology Highlights

    AVEO Oncology Highlights Retained significant North American rights for all oncology therapeutic assets Executing on development strategies for tivozanib Enrolling Ph 3 refractory RCC study (TIVO-3) to support 1st & 3rd line indications Enrolling Ph 1/2 tivozanib + Opdivo® combination study (TiNivo)

  32. Slide 32: AVEO Overview April 2017

    AVEO Overview April 2017

AVEO Pharmaceuticals — Investor Presentation (April 2017) on 6ix